InteRNA Technologies Announces Closing of Equity Financing Round
News Sep 06, 2013
InteRNA Technologies B.V. has announced the closing of an equity financing round. New investors participating in this round include the ‘Innovation & Investment Fund Gelderland’, managed by PPM Oost and several business angels.
The proceeds of this financing will be used to progress lead product candidate, miR-3157, for melanoma through preclinical studies towards clinical development.
miR-3157 is a microRNA-based compound that has shown outstanding efficacy data in initial preclinical studies of human melanoma. These data were presented at the Society for Melanoma Research Congress in November 2012.
Recently, the Company was granted US patent 8,362,230, conferring broad and strong IP protection for miRNA-3157 and related compounds.
InteRNA has developed a promising platform for discovery and validation of miRNA based drug candidates against previously undruggable targets in cancer and other major diseases.
In addition to its own miR-3157 program, the Company intends to partner development of other compounds with selected pharmaceutical companies.
“Building on our leadership position in the field of miRNA-based drugs, and backed by a strong and broad intellectual property position on a large collection of potential miRNA drug candidates, InteRNA is building a competitive pipeline of breakthrough therapeutics, both through internal development and in collaboration with partners. The present funding provides us additional resources to progress development of our lead compound and further validate the power of our platform”, said Roel Schaapveld, CEO of InteRNA Technologies.
"Genetic Jenga" Helps Understand How Our Genes Control Our CellsNews
To fully understand how our cells work, we can't focus on just one gene, but must instead look at combinations of genes. Researchers have published a study which knocked out multiple genes, like removing bricks from a Jenga tower, to better understand how they work together.READ MORE
Southeast Asian Nomads Have Evolved to Hunt Fish UnderwaterNews
The human spleen can release oxygenated blood cells to allow more time underwater without breathing. A new study has identified that the "Sea Nomad" Bajau people of Indonesia have evolved larger spleens that would allow them to remain underwater for longer.READ MORE
Gene Therapy Could End Transfusions for Blood Disorder PatientsNews
Beta-thalassemia patients need a regular dose of red blood cells transfused into their body. A new gene therapy that edits faulty genes in the patients' cells could end this monthly ritual.READ MORE
Comments | 0 ADD COMMENT
International Conference on Epigenetics and Epitranscriptomics
Sep 17 - Sep 18, 2018